Quest Diagnostics Incorporated (DGX) Earnings

Management highlights

- Strategic Execution & Channel Growth - The company is focused on its core strategy of connecting patients and providers with innovative testing and actionable health insights, serving core physician/hospital customers and higher-growth consumer health, life sciences, and data analytics segments. - Physician channel growth is supported by expanded geographic reach from recent health plan access expansions and acquisitions, growing enterprise accounts focused on prevention and wellness, and the Fresenius collaboration that builds capabilities to serve the 36 million people in the U.S. with chronic kidney disease. - Hospital channel growth is driven by strategic co-lab partnerships that help hospitals address workforce and financial pressures by improving quality, expanding access to new tests, and cutting costs; a new co-lab agreement was signed with a California nonprofit regional health system in Q2, building a strong pipeline of future collaborations, hospital outreach acquisitions, and independent lab acquisitions. - Consumer Health growth is fueled by rising demand for proactive preventative wellness; the company continues to expand its direct-to-consumer platform and partner solutions, leveraging diagnostic innovation and flexible technology integration. - High-growth priority clinical areas include advanced cardiometabolic/endocrine testing, autoimmune diagnostics, brain health, oncology, and women's/reproductive health, all of which delivered double-digit revenue growth in the quarter. - Key Milestones & Innovation - Haystack MRD, the company's solid tumor ctDNA MRD test, received New York State approval, allowing commercial launch across all 50 states; Haystack MRD was also added to Flatiron Health's OncoEMR molecular profiling integration platform, with a pilot underway at the American Oncology Network and full national rollout to 4,700+ clinicians planned for late 2026. - Operational technology investments are driving quality and productivity gains: the AI-powered WholeLogic Genius Digital Diagnostic System for cervical cancer Pap test review was rolled out to two additional lab locations (with six prior implementations), front-end specimen processing automation is delivering measurable productivity gains, and new tools including the web-based IntelliDraw specimen collection guidance tool and an AI-powered supply tracking tool for patient service centers will launch in 2026. - Operational Excellence - The company remains on track to deliver 3% annual cost savings and productivity improvements through its Invigorate program. - New Head of Investor Relations Dominique Chokshi joined the company last week, with Dan Haemmerle supporting her transition.

Guidance

- The company raised its full-year 2026 guidance following strong first-half performance and sustained growth momentum. - Full-year 2026 revenue is now expected to be between $11.95 billion and $12.05 billion, representing year-over-year growth of 8.3% to 9.2%. The guidance does not include any potential contributions from future mergers and acquisitions. - Full-year 2026 reported diluted EPS is guided to a range of $9.97 to $10.17, and adjusted diluted EPS is guided to $11.05 to $11.25. - Full-year 2026 cash from operations is expected to be approximately $1.8 billion, with capital expenditures of approximately $550 million. - Operating margin is expected to expand year-over-year despite headwinds including higher second-half NOVA investment spend than previously anticipated, higher-than-expected second-half fuel costs (now expected to be at the high end of the prior guidance range, totaling ~$10 million for the full year). - A 30 basis point revenue headwind from the expiration of ACA exchange subsidies is still maintained in full-year guidance, consistent with prior outlooks. - Additional guidance assumptions include: share count slightly below 2025 levels, interest expense consistent with 2025, and an adjusted effective tax rate consistent with 2025. - Core utilization is expected to remain strong in the second half of 2026, consistent with trends seen in Q2.

Segment performance

In Q2 2026, Quest Diagnostics reported consolidated revenues of $3.04 billion, a 10.2% year-over-year increase, with 10% organic revenue growth. The company's primary operating segment is Diagnostic Information Services, which generated 10.3% year-over-year revenue growth with 10.1% organic growth, accounting for nearly 100% of total consolidated revenue. By customer channel: Physician channel delivered high single-digit revenue growth, driven by broad clinical demand, new customer wins, and the existing Fresenius Medical Care collaboration. Hospital channel grew revenues at a double-digit rate, primarily from the CoLab Solutions collaboration with Corwell Health; reference testing revenue also grew quarter-over-quarter and year-over-year. Consumer Health channel saw robust revenue growth, led by strong demand for existing wellness panels and new services (such as thyroid testing) on the direct-to-consumer platform questhealth.com. By key clinical area: Double-digit revenue growth was achieved across multiple high-priority segments, including advanced cardiometabolic testing, autoimmune disorder diagnostics, brain health Alzheimer's detection blood tests, and oncology. Total requisition volume increased 13.1% year-over-year, with 13% organic volume growth; the Corwell and Fresenius relationships contributed 9% to total volume, while volume excluding these relationships grew 4.1%. Reported operating income was $459 million (15.1% of revenue), compared to $438 million (15.9% of revenue) in Q2 2025. Adjusted operating income was $502 million (16.5% of revenue), compared to $466 million (16.9% of revenue) year-over-year. Reported diluted EPS was $2.84, compared to $2.47 year-over-year; adjusted diluted EPS was $3.12, compared to $2.62 year-over-year, representing 19.1% adjusted EPS growth. Year-to-date cash from operations through Q2 was $875 million, up from $858 million in the prior year.

Risks & headwinds

- Uncertainty around the PAMA clinical laboratory reimbursement rule implementation, including potential for unexpected large reimbursement cuts if the current flawed data collection process results in new low rates being implemented in 2027. - Potential worsening impact from ACA exchange enrollment reductions following subsidy expiration that could negatively impact revenue in the second half of 2026, even though no material impact has been seen to date. - Third quarter weather disruption is always a wildcard that could negatively impact volumes and results. - Ramp-up of the Corwell CoLab business, investment spending on Project Nova, and higher supplemental deferred compensation expenses created near-term margin pressure in Q2 2026. - Elevated fuel costs in the second half of 2026 are expected to create a headwind to profitability.

Analyst Q&A

• Q: Erin Wright of Morgan Stanley asked for an update on hospital channel growth, deal pipeline, and bad debt exposure from co-lab relationships, given broader hospital industry headwinds. /

  A: Quest's hospital business has two segments: pure reference testing, which grew mid-single digits with no slowdown in demand, and co-lab partnerships, which saw mid-single-digit same-store growth excluding the new Corwell Health relationship. Management noted a strong pipeline of new hospital co-lab, outreach, and acquisition opportunities, and reported that bad debt is not a concern, with no adverse bad debt trends seen across hospital relationships to date. (312 characters)

• Q: Lisa Gill of JP Morgan asked for an update on the 30 basis point ACA/Medicaid headwind assumption, including Q2 impacts and whether it remains in updated guidance. /

  A: The 30 basis point full-year revenue headwind assumption is maintained in guidance. While ACA exchange enrollment is down ~21%, this has not translated to material revenue impact: requisition volume is down 8%, but tests per requisition are up 6% (sicker patients remain enrolled after healthier people dropped coverage), leaving total test volume down only 2% and revenue roughly flat. (330 characters)

• Q: Michael Cherney of Leerink Partners asked what offsets will drive the expected full-year operating margin expansion in the second half of 2026, against higher NOVA spending and fuel costs. /

  A: Q2 2026 operating margin was 16.5%, 40 basis points below last year, driven by 70 basis points of headwinds from NOVA investment, Corwell/Fresenius business mix dilution, and mark-to-market impacts on supplemental deferred compensation plans. Key offsets for the second half include continued strong volume growth, and lapping the Corwell and Fresenius ramp in Q4, which reduces their margin dilution impact. (354 characters)

• Q: Pito Chickering of Deutsche Bank asked how New York State approval and the Flatiron Health partnership will impact Haystack MRD volume growth. /

  A: New York State's rigorous approval process sends a strong signal of Haystack's quality and opens access to major cancer centers across the state, a large important oncology market. The Flatiron integration simplifies ordering for thousands of clinicians nationwide. Management is pacing commercial growth and investment in line with reimbursement progress, and is awaiting Medicare Advantage reimbursement decisions expected in the second half. (338 characters)

• Q: Jack Meehan of Oberon Research asked for an update on the PAMA policy outlook and prospects for the Results Act. /

  A: There are three possible outcomes. First, the current CMS data collection process ends July 31, with results expected in late September/early October; last cycle only 1% of labs submitted data, creating a biased sample. Second, the bipartisan Results Act, which fixes PAMA's flaws by using a third-party to collect unbiased adjudicated claims data, has 115+ co-sponsors and broad stakeholder support, and management continues to push for its passage. If the Results Act is not passed this year, management expects another delay to implementation, as Congress has already delayed PAMA six times acknowledging the original process was flawed. (458 characters)